Novo Nordisk A/S

Novo Nordisk maintains a capital structure characterized by significant leverage, with a debt-to-equity ratio of 0.67 and long-term debt totaling DKK 130.96 billion against total equity of DKK 194.05 billion. The balance sheet shows total assets of DKK 542.90 billion and total liabilities of DKK 348.86 billion. Liquidity is assessed as medium risk, supported by a current ratio of 0.8, which indicates that current liabilities exceed current assets. The company generated DKK 119.10 billion in operating cash flow but reported negative free cash flow of DKK -24.78 billion due to substantial capital expenditures of DKK 90.11 billion.

Profitability metrics demonstrate strong returns on capital, with a return on equity (ROE) of 62.85% and a return on assets (ROA) of 22.46%. The company reported revenue of DKK 309.06 billion, resulting in a gross profit of DKK 256.06 billion and operating income of DKK 127.66 billion. Net income stands at DKK 102.43 billion, reflecting efficient conversion of operating income to bottom-line earnings. These returns significantly exceed typical industry medians for pharmaceutical firms, indicating superior operational efficiency and pricing power.

Segment and geographic revenue mix data is not available in the provided input, preventing a detailed analysis of revenue concentration or regional exposure. The analysis relies solely on consolidated financial figures, omitting specific product or regional breakdowns due to data absence.

Growth trajectory analysis is limited by the absence of historical period data in the input. Without multi-year revenue or net income trends, the company's growth momentum cannot be quantified against past performance. The current snapshot reflects a single normalized period, precluding trend-based reasoning.

Risk assessment highlights medium liquidity risk and low dilution risk. A key flag notes that net cash is negative after subtracting total debt, emphasizing the reliance on debt financing. The negative free cash flow position further underscores the capital-intensive nature of the current operational cycle, driven by high capital expenditures.

Recent observations include analyst estimates with a mean price target of DKK 323.38 and a median target of DKK 305.00. The mean recommendation is 2.67, with 4 strong buys, 6 buys, and 21 holds, indicating a cautious but positive sentiment among analysts. No specific filing, news, or transcript observations were provided to detail recent corporate events.

Novo Nordisk A/S (NOVOB.CO) experienced significant volatility in its institutional ownership structure, marked by major holder changes detected in late June and early July 2026. Two specific investors, identified by IDs 931 and 587, underwent substantial modifications to their shareholdings as of March 31, 2026. These adjustments involved dramatic swings in position sizes, with one investor’s stake fluctuating between approximately 4,000 and 428,000 shares, and another’s shifting between roughly 18,000 and 404,000 shares. The magnitude of these changes is notable, with the value of the affected positions ranging from roughly $0.15 million to $15.45 million. For investor ID 931, the weight of the holding in the portfolio shifted from a negligible 0.00007% to 0.74%, and vice versa, indicating a complete reversal or correction in reported data. Similarly, investor ID 587 saw their portfolio weight oscillate between 0.04% and 0.86%, reflecting a major reallocation or reporting adjustment of their exposure to the Danish pharmaceutical giant. Despite these pronounced movements in the shareholder register, the broader fundamental profile of Novo Nordisk remained stable during this period. The company continues to be tracked by 10 analysts and maintains a top holder count of 32, suggesting that while specific institutional positions were in flux, the overall investor base structure did not undergo a systemic collapse or expansion. The officer count remained at two, indicating no changes in the executive leadership team that might have triggered these trading activities. The absence of material changes in the company’s core operational or financial metrics, as noted in the prior analysis, suggests that these holder modifications were likely driven by specific institutional rebalancing or data corrections rather than a reaction to new corporate developments. With no new cross-source signals or sagas reported, the significance of these events lies primarily in the transparency of the ownership data, highlighting the dynamic nature of institutional positioning in NOVOB.CO even amidst a period of fundamental stability.

Revenue grew at a 21.7% CAGR over four years, demonstrating strong top-line expansion momentum.

Net income expanded at a 21.0% CAGR, indicating robust profitability growth alongside revenue increases.

Debt-to-equity ratio of 0.67 is below median, indicating higher leverage than the 0.4 cohort median.

Cash conversion of 0.98 is below the 1.2 cohort median, signaling weaker cash generation efficiency.

Revenue kr 96.82B, +24,0% YoY; Operating income +53,7% YoY.

• ▍Revenue kr 96.82B, +24,0% YoY
• ▍Operating income +53,7% YoY
• ▍Net income +67,2% YoY
• ▍Free cash flow +127,9% YoY
• ▍Net margin 50.2%

Revenue kr 79.14B, −7,6% YoY; Operating income −13,6% YoY.

• ▍Revenue kr 79.14B, −7,6% YoY
• ▍Operating income −13,6% YoY
• ▍Net income −4,7% YoY
• ▍Free cash flow −158,1% YoY
• ▍Net margin 34.0%

Revenue kr 74.98B, +5,1% YoY; Operating income −30,0% YoY.

• ▍Revenue kr 74.98B, +5,1% YoY
• ▍Operating income −30,0% YoY
• ▍Net income −26,7% YoY
• ▍Free cash flow −519,2% YoY
• ▍Net margin 26.7%

Revenue kr 76.86B, +12,9% YoY; Operating income +29,0% YoY.

• ▍Revenue kr 76.86B, +12,9% YoY
• ▍Operating income +29,0% YoY
• ▍Net income +32,2% YoY
• ▍Free cash flow +46,6% YoY
• ▍Net margin 34.5%

Revenue kr 78.09B; Operating income kr 38.79B.

• ▍Revenue kr 78.09B
• ▍Operating income kr 38.79B
• ▍Net margin 37.2%

Revenue kr 85.68B; Operating income kr 36.74B.

• ▍Revenue kr 85.68B
• ▍Operating income kr 36.74B
• ▍Net margin 32.9%

Revenue kr 71.31B; Operating income kr 33.82B.

• ▍Revenue kr 71.31B
• ▍Operating income kr 33.82B
• ▍Net margin 38.3%

Revenue kr 68.06B; Operating income kr 25.93B.

• ▍Revenue kr 68.06B
• ▍Operating income kr 25.93B
• ▍Net margin 29.5%

Revenue kr 309.06B, +6,4% YoY; Operating income −0,5% YoY.

• ▍Revenue kr 309.06B, +6,4% YoY
• ▍Operating income −0,5% YoY
• ▍Net income +1,4% YoY
• ▍Free cash flow −275,9% YoY
• ▍Net margin 33.1%

Revenue kr 290.40B, +25,0% YoY; Operating income +25,1% YoY.

• ▍Revenue kr 290.40B, +25,0% YoY
• ▍Operating income +25,1% YoY
• ▍Net income +20,7% YoY
• ▍Free cash flow −30,6% YoY
• ▍Net margin 34.8%

Revenue kr 232.26B, +31,3% YoY; Operating income +37,1% YoY.

• ▍Revenue kr 232.26B, +31,3% YoY
• ▍Operating income +37,1% YoY
• ▍Net income +50,7% YoY
• ▍Free cash flow −7,8% YoY
• ▍Net margin 36.0%

Revenue kr 176.95B, +25,7% YoY; Operating income +27,6% YoY.

• ▍Revenue kr 176.95B, +25,7% YoY
• ▍Operating income +27,6% YoY
• ▍Net income +16,3% YoY
• ▍Free cash flow −8,9% YoY
• ▍Net margin 31.4%